Moderna, Inc.
MRNAModerna, Inc. (/məˈdɜːrnə/ mə-DUR-nə) is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
Drugs in Pipeline
47
Phase 3 Programs
20
Upcoming Catalysts
6
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
6 upcoming, 6 past
How MRNA's past catalysts played out
mRNA-1283
COVID-19
mRNA-1010
Seasonal Influenza
mRNA-4157
Personalized Cancer Vaccine
Melanoma
Fluarix Tetra
Seasonal Influenza
mRNA-1403
Acute Gastroenteritis
mRNA-1273.214
SARS-CoV-2
mRNA-1083
COVID-19
mRNA-1345
Respiratory Syncytial Virus
mRNA-1273
SARS-CoV-2
Influenza Vaccine
SARS-CoV-2
Fluarix®
Seasonal Influenza
Investigational mRNA-1273.815
SARS-CoV-2
Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine
Seasonal Influenza
mRNA-1283.222
COVID-19
mRNA-1273.211
SARS-CoV-2
Fluzone HD
Respiratory Syncytial Virus
mRNA-1018-H5
Influenza
Intismeran autogene
Non-small Cell Lung Cancer
Moderna COVID-19 Vaccine, mRNA-1273 (100 μg)
Immunocompromised Patients
mRNA-1283.815
COVID-19
mRNA-1283.211
SARS-CoV-2
Active Comparator
Seasonal Influenza
mRNA-1468
Herpes Zoster
mRNA-1893
Zika Virus
mRNA-1982
Lyme Disease
mRNA-1083 Composition 1 Dose A Lot A
Influenza
mRNA-3705
Methylmalonic Acidemia
mRNA-3745
Glycogen Storage Disease
mRNA-1010.4
Influenza
mRNA-1273.214 Vaccine
COVID-19 Pandemic
Egg-based Quadrivalent Influenza Vaccine
Influenza
mRNA-1195
Multiple Sclerosis
mRNA-1011.1
Seasonal Influenza
mRNA-1405
Norovirus Acute Gastroenteritis
Biological: mRNA-1273
SARS-CoV-2
mRNA-1647
Cytomegalovirus Infection
mRNA-1030
Seasonal Influenza
mRNA-1769
Smallpox
mRNA-1608
Genital Herpes
mRNA-1018 for H5N8
Influenza
mRNA-4359
Advanced Solid Tumors
mRNA-3927
Propionic Acidemia
mRNA-1189
Epstein-Barr Virus Infection
mRNA-1975
Lyme Disease
mRNA-1073
SARS-CoV-2
Influenza Vaccine 1
SARS-CoV-2
mRNA-2808
Relapsed or Refractory Multiple Myeloma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
mRNA-1283 | Phase 3 | COVID-19 | Fast Track | - |
mRNA-1010 | Phase 3 | Seasonal Influenza | Fast Track | - |
mRNA-4157 Personalized Cancer Vaccine | Phase 3 | Melanoma | OrphanFast TrackBreakthrough | - |
Fluarix Tetra | Phase 3 | Seasonal Influenza | - | - |
mRNA-1403 | Phase 3 | Acute Gastroenteritis | - | - |
mRNA-1273.214 | Phase 3 | SARS-CoV-2 | - | - |
mRNA-1083 | Phase 3 | COVID-19 | - | - |
mRNA-1345 | Phase 3 | Respiratory Syncytial Virus | - | - |
mRNA-1273 | Phase 3 | SARS-CoV-2 | - | - |
Influenza Vaccine | Phase 3 | SARS-CoV-2 | - | - |
Fluarix® | Phase 3 | Seasonal Influenza | - | - |
Investigational mRNA-1273.815 | Phase 3 | SARS-CoV-2 | - | - |
Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine | Phase 3 | Seasonal Influenza | - | - |
mRNA-1283.222 | Phase 3 | COVID-19 | - | - |
mRNA-1273.211 | Phase 3 | SARS-CoV-2 | - | - |
Fluzone HD | Phase 3 | Respiratory Syncytial Virus | - | - |
mRNA-1018-H5 | Phase 3 | Influenza | - | - |
Intismeran autogene | Phase 3 | Non-small Cell Lung Cancer | - | - |
Moderna COVID-19 Vaccine, mRNA-1273 (100 μg) | Phase 3 | Immunocompromised Patients | - | - |
mRNA-1283.815 | Phase 3 | COVID-19 | - | - |
mRNA-1283.211 | Phase 2 | SARS-CoV-2 | - | - |
Active Comparator | Phase 2 | Seasonal Influenza | - | - |
mRNA-1468 | Phase 2 | Herpes Zoster | - | - |
mRNA-1893 | Phase 2 | Zika Virus | - | - |
mRNA-1982 | Phase 2 | Lyme Disease | - | - |
mRNA-1083 Composition 1 Dose A Lot A | Phase 2 | Influenza | - | - |
mRNA-3705 | Phase 2 | Methylmalonic Acidemia | - | - |
mRNA-3745 | Phase 2 | Glycogen Storage Disease | - | - |
mRNA-1010.4 | Phase 2 | Influenza | - | - |
mRNA-1273.214 Vaccine | Phase 2 | COVID-19 Pandemic | - | - |
Egg-based Quadrivalent Influenza Vaccine | Phase 2 | Influenza | - | - |
mRNA-1195 | Phase 2 | Multiple Sclerosis | - | - |
mRNA-1011.1 | Phase 2 | Seasonal Influenza | - | - |
mRNA-1405 | Phase 2 | Norovirus Acute Gastroenteritis | - | - |
Biological: mRNA-1273 | Phase 2 | SARS-CoV-2 | - | - |
mRNA-1647 | Phase 2 | Cytomegalovirus Infection | - | - |
mRNA-1030 | Phase 2 | Seasonal Influenza | - | - |
mRNA-1769 | Phase 2 | Smallpox | - | - |
mRNA-1608 | Phase 2 | Genital Herpes | - | - |
mRNA-1018 for H5N8 | Phase 2 | Influenza | - | - |
mRNA-4359 | Phase 2 | Advanced Solid Tumors | - | - |
mRNA-3927 | Phase 2 | Propionic Acidemia | - | - |
mRNA-1189 | Phase 2 | Epstein-Barr Virus Infection | - | - |
mRNA-1975 | Phase 2 | Lyme Disease | - | - |
mRNA-1073 | Phase 2 | SARS-CoV-2 | - | - |
Influenza Vaccine 1 | Phase 2 | SARS-CoV-2 | - | - |
mRNA-2808 | Phase 2 | Relapsed or Refractory Multiple Myeloma | - | - |
Influenza
6 drugs in this indication
Respiratory Syncytial Virus
1 drug in this indication
COVID-19
1 drug in this indication
Melanoma
1 drug in this indication
norovirus
1 drug in this indication
Active immunization for the prevention of lower respiratory tract disease caused by RSV
1 drug in this indication
diabetes
1 drug in this indication
Respiratory Syncytial Virus (RSV)
1 drug in this indication
Seasonal Influenza
1 drug in this indication
flu
1 drug in this indication
flu prevention
1 drug in this indication
influenza prevention
1 drug in this indication
Ebola
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Moderna, Inc.'s drug pipeline?→
CatalystAlert tracks 47 drug candidates in Moderna, Inc.'s (MRNA) pipeline across Phase 3, Phase 2. Its lead program is mRNA-1283 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Moderna, Inc.'s next FDA catalyst?→
Moderna, Inc.'s (MRNA) next tracked catalyst is a NDA Filing expected August 1, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MRNA biotech catalysts?→
Add MRNA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Moderna, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.